MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM
Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in
Lian Cardiovascular and
LianBio was recently launched by
“Hypertrophic cardiomyopathy is estimated to affect more than one million people in
Mavacamten will serve to anchor the portfolio for LianBio’s cardiorenal-focused subsidiary, Lian Cardiovascular. Lian Cardiovascular has assembled a strong team across development, regulatory and other key functions, including
“The partnership with LianBio is consistent with MyoKardia’s strategy of adding capabilities to extend our efforts to bring precision cardiovascular therapeutics to patients in need while maintaining both significant influence on our global brand and economic rights,” said
“We have structured LianBio with the intent of greatly expanding our partner’s ability to succeed as we work together to bring exciting new therapeutics to patients in need,” added
In addition to its equity position, under the terms of the agreement,
About Mavacamten (MYK-461)
Mavacamten is initially being developed for the treatment of hypertrophic cardiomyopathy (HCM) and has received breakthrough therapy and orphan drug designations for symptomatic, obstructive HCM.
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
MyoKardia Forward-Looking Statement
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding mavacamten’s successful development for the treatment of patients with HCM and, in some instances, HFpEF, as well as non-obstructive HCM, our registration strategy for mavacamten in
Michelle CorralExecutive Director, Corporate Communications and Investor Relations MyoKardia, Inc.650-351-4690 firstname.lastname@example.org Hannah Deresiewicz(investors) Stern Investor Relations, Inc. 212-362-1200 email@example.com Julie Normant(media) W2O 628-213-3754 firstname.lastname@example.org
Source: MyoKardia, Inc.